Lysosomal Storage Disease Market To Reach $16.63 Billion by 2035

Lysosomal Storage Disease market was valued at $9.61 billion in 2025 and is projected to reach $16.63 billion by 2035, growing at a CAGR of 5.6% during the forecast period (2026–2035). The increasing prevalence of rare genetic disorders and growing advancements in orphan drug development are major macro drivers supporting market growth globally. According to the World Health Organization (WHO), congenital disorders contribute to approximately 240,000 newborn deaths globally every year within the first 28 days of life. Increasing implementation of newborn screening programs and rising awareness regarding inherited metabolic disorders are accelerating early diagnosis and treatment adoption for lysosomal storage diseases worldwide.

Browse the full report description of “Lysosomal Storage Disease Market Size, Share & Trends Analysis Report, By Disease Type (Gaucher Disease, Fabry Disease, Pompe Disease, Niemann-Pick Disease, Mucopolysaccharidoses (MPS), Krabbe Disease, Tay-Sachs Disease, Others), By Therapy Type (Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT), Gene Therapy, Stem Cell Therapy, Small Molecule Therapy, Supportive & Symptomatic Treatment), By End User (Hospitals, Specialty Clinics, Research & Academic Institutes, Homecare Settings), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/lysosomal-storage-disease-market

The increasing burden of rare diseases is significantly supporting market expansion. According to the National Institutes of Health (NIH), lysosomal storage disorders collectively affect approximately 1 in every 5,000 to 8,000 live births globally. In addition, the U.S. Food and Drug Administration (FDA) continues to support orphan drug approvals and expedited pathways for rare disease therapeutics, encouraging pharmaceutical innovation in enzyme replacement therapies and gene therapies. Rising healthcare expenditure, growing biotechnology investments, and increasing patient access programs are further strengthening market growth. Hospitals and specialty clinics continue to dominate the end-user segment owing to increasing demand for specialized diagnostic services and long-term disease management solutions.

Growing Demand for Gene Therapy and Enzyme Replacement Therapy Supporting Market Growth

The therapy type segment is witnessing strong growth due to increasing adoption of advanced biologic therapies and precision medicine approaches for rare genetic disorders. Enzyme replacement therapy (ERT) remains the dominant segment owing to its established clinical effectiveness in treating Gaucher disease, Fabry disease, and Pompe disease. However, gene therapy is expected to witness rapid growth due to increasing investments in viral vector technologies, genetic engineering, and curative treatment approaches. Pharmaceutical and biotechnology companies are strengthening research collaborations and expanding rare disease pipelines between 2024 and 2026 to improve long-term treatment outcomes. Homecare settings are also emerging as a fast-growing end-user segment due to increasing preference for long-term infusion-based therapies and supportive care management outside hospital settings.

Key Leaders Transforming the Lysosomal Storage Disease Market

The key players in the lysosomal storage disease market include Sanofi, Takeda Pharmaceuticals, BioMarin Pharmaceutical, Amicus Therapeutics, AstraZeneca, among others. These companies are focusing on orphan drug development, strategic partnerships, acquisitions, and geographical expansion strategies to strengthen their market presence.

• In April 2026, BioMarin Pharmaceutical completed the acquisition of Amicus Therapeutics in an all-cash transaction valued at approximately $4.8 billion. The acquisition strengthens BioMarin’s rare disease portfolio by adding Galafold® for Fabry disease and Pombiliti® + Opfolda® therapies for Pompe disease, while expanding the company’s commercial presence in lysosomal storage disorder treatments globally.
• In March 2026, Takeda Pharmaceuticals announced the next phase of its global transformation strategy to strengthen competitiveness, enhance long-term growth, and accelerate launch execution. The company stated that the initiative is expected to generate annualized gross savings of more than JPY 200 billion by FY2028 through operational streamlining, organizational restructuring, and advanced technology integration to support future product launches and pipeline expansion.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
• Disease Type
• Therapy Type
• End User
• Competitive Landscape – Sanofi, Takeda Pharmaceuticals, BioMarin Pharmaceutical, Amicus Therapeutics, AstraZeneca, among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Lysosomal Storage Disease Market Segmentation

By Disease Type

• Gaucher Disease
• Fabry Disease
• Pompe Disease
• Niemann-Pick Disease
• Mucopolysaccharidoses (MPS)
• Krabbe Disease
• Tay-Sachs Disease
• Others

By Therapy Type

• Enzyme Replacement Therapy (ERT)
• Substrate Reduction Therapy (SRT)
• Gene Therapy
• Stem Cell Therapy
• Small Molecule Therapy
• Supportive & Symptomatic Treatment

By End User

• Hospitals
• Specialty Clinics
• Research & Academic Institutes
• Homecare Settings

Global Lysosomal Storage Disease Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/lysosomal-storage-disease-market